PRECISIONBIOLOGICS
Menu
↗
Science

Growth factor panels are analytical, not clinical

Why growth-factor panels on perinatal products should be filed as analytical data, not outcome evidence.

Reviewed 2026-10-27

What panels show

Panels list detected factors under a method. They do not prove a patient outcome.

Accept panels as characterization when lot-linked; reject panels used as disease marketing.

Buyer practice

Decide with your quality program whether a panel is required to buy.

Panels never substitute for sterility or release evidence.

Keep file language consistent

Confirm tissue type on the label. Do not treat amniotic and Wharton's jelly SKUs as interchangeable because both are perinatal.

Keep separate vendor files per tissue type.

Operational checklist for growth factor panel biologics analytical

Before ordering under the topic growth factor panel biologics analytical, confirm storage class, receiving owner, and which documents will be required at release.

Close open items in writing. Do not infer missing COA fields from a different lot or SKU.

FAQ

Frequently asked questions

Does an analytical figure prove clinical performance?+

No. Analytical figures characterize a lot; they are not clinical endpoints.

Should we call these stem cell products?+

No. Precision Biologics does not market these items as stem cell therapies.

Can literature replace a COA?+

No. File literature separately from lot evidence.

Does this page determine how we may use products discussed under growth factor panel biologics analytical?+

No. Intended use remains with the ordering physician and clinic counsel.

Sources

  1. ISCT MSC minimal criteria (2006) ↗PubMed
  2. FDA: Minimal Manipulation and Homologous Use guidance ↗FDA